Clinical data show significant reductions in both pain and inflammation in RA and inflammatory bowel disease patients treated with sulfasalazine [36], an inhibitor of sepiapterin reductase [37] leading to reduced BH4 levels. The gene discussed is SPR; the disease is rheumatoid arthritis.